Dupixent Lawsuit

For many people living with severe eczema, asthma, and other chronic inflammatory conditions, Dupixent offered hope after years of struggling to control painful symptoms. Unfortunately, some patients who relied on this medication are now facing a far more serious diagnosis: cutaneous T-cell lymphoma (CTCL) or another form of T-cell lymphoma.

Pending lawsuits filed against Dupixent’s manufacturers allege that patients and healthcare providers were not adequately warned that long-term use of the drug could be associated with lymphoma. As additional scientific research emerges and more harmed patients come forward, litigation continues to grow nationwide.

If you or a loved one used Dupixent and were later diagnosed with cutaneous T-cell lymphoma or another T-cell lymphoma, you may have legal options. The mass tort attorneys at Hach & Rose, LLP are accepting these claims and helping patients understand whether they may qualify to pursue compensation.

Do You Qualify to File a Dupixent Lawsuit?

You may have a potential legal claim if you:

• Used Dupixent (dupilumab) to treat eczema, atopic dermatitis, asthma, or another approved condition.
• Later developed cutaneous T-cell lymphoma (CTCL) or another T-cell lymphoma.
• Required biopsies, chemotherapy, radiation therapy, immunotherapy, surgery, or ongoing cancer treatment.
• Believe you were never adequately warned about the potential lymphoma risk.

Call Hach & Rose, LLP today at (212) 779-0057 for a free, confidential case evaluation. You pay no attorney’s fees unless we recover compensation for you.

Why Choose Hach & Rose, LLP for Your Dupixent Lawsuit?

Taking on large pharmaceutical companies requires experience, substantial resources, and a willingness to challenge corporations that often have teams of defense lawyers and scientific experts working on their behalf.

For more than 25 years, Hach & Rose, LLP has represented individuals and families harmed by negligence, dangerous products, and other serious misconduct. During that time, our firm has recovered more than $1 billion through settlements and verdicts for our clients while taking on large corporations, insurance companies, and other powerful defendants.

Emerging pharmaceutical litigation, like the Dupixent lawsuits, requires more than simply reviewing medical records. Our attorneys work with medical experts, analyze complex scientific evidence, evaluate pharmaceutical warnings, negotiate with manufacturers and their insurers, and, when necessary, present compelling cases in court. We are committed to helping our clients pursue the compensation they deserve while holding drug manufacturers accountable for alleged failures to adequately warn patients about serious risks.

We understand that a lymphoma diagnosis affects every aspect of your life. Our goal is to help you navigate the legal process while you focus on your health and recovery. Your consultation is always free, and because we work on a contingency fee basis, you pay nothing unless we recover compensation on your behalf.

What Our Clients Say About Us

Read More Reviews

What Is Dupixent?

Dupixent® (dupilumab) is a prescription biologic medication jointly developed by Sanofi and Regeneron Pharmaceuticals. Unlike traditional medications, biologics target specific parts of the immune system involved in chronic inflammatory diseases.

The U.S. Food and Drug Administration (FDA) has approved Dupixent to treat several conditions, including:

• Moderate-to-severe atopic dermatitis (eczema)
• Certain forms of asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis
• Chronic obstructive pulmonary disease (COPD) in certain patients

Because it can significantly improve symptoms that have not responded to other treatments, Dupixent has become one of the most widely prescribed biologic medications worldwide.

For many patients, the medication provides meaningful relief from chronic itching, skin inflammation, or breathing difficulties. However, lawsuits now allege that some users developed serious cancers after taking the drug and were never adequately informed of the potential risks.

Why Are People Filing Dupixent Lawsuits?

The current Dupixent litigation focuses on allegations that prolonged use of the medication may be associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and other T-cell lymphomas.

Plaintiffs allege that Sanofi and Regeneron failed to adequately warn physicians and patients about the potential lymphoma risk associated with Dupixent. The lawsuits further contend that the companies continued to market the drug aggressively despite emerging safety concerns and failed to provide sufficient information to help healthcare providers recognize warning signs warranting additional evaluation.

Like all pharmaceutical litigation, these allegations must ultimately be proven in court. The manufacturers deny wrongdoing, and the litigation remains ongoing.

What is the FDA Warning and Emerging Medical Research?

As reports of lymphoma diagnoses increased, researchers began examining whether there could be a connection between Dupixent treatment and certain T-cell lymphomas.

In response to emerging evidence, the FDA updated Dupixent’s prescribing information to include additional safety information regarding lymphoma. Researchers have also published studies describing patients who were initially treated for severe eczema before later being diagnosed with cutaneous T-cell lymphoma.

One challenge is that early-stage CTCL often resembles eczema, making diagnosis difficult. Some patients continue receiving Dupixent while physicians attempt to manage what appears to be persistent atopic dermatitis, only to discover later through biopsy that the underlying condition is actually lymphoma.

While research continues, plaintiffs argue the manufacturers should have acted sooner to strengthen warnings and help physicians recognize these potential risks.

Current Status of the Dupixent Litigation (2026 Update)

Dupixent lawsuits are still in the early stages, but new claims continue to be filed by patients who allege they developed lymphoma after using the medication.

As attorneys investigate additional cases, courts are expected to address common scientific and legal issues regarding whether Dupixent contributed to the development or progression of cutaneous T-cell lymphoma. As with many emerging pharmaceutical mass torts, the litigation will likely continue to evolve as more medical evidence becomes available.

Because this is still an active and developing area of litigation, individuals who believe they may have a claim should seek legal advice as soon as possible. Taking legal action quickly can help preserve important medical records, prescription history, proof of symptoms, and other evidence that may support a future lawsuit.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects T lymphocytes, a type of white blood cell that plays an important role in the immune system.

Unlike many cancers that begin in internal organs, CTCL primarily affects the skin. Early symptoms frequently resemble common skin conditions, which is one reason diagnosis is often delayed.

As the disease progresses, CTCL may spread beyond the skin to lymph nodes, blood, or internal organs, requiring more aggressive treatment. Because early CTCL can closely resemble eczema, some patients spend months or even years seeking relief before receiving the correct diagnosis.

Symptoms of Cutaneous T-Cell Lymphoma

Because cutaneous T-cell lymphoma often resembles eczema during its earliest stages, many patients do not realize they have cancer until their symptoms worsen or fail to respond to treatment. Some individuals spend months—or even years—trying different medications before receiving the correct diagnosis.

Symptoms vary from person to person but commonly include:

• Persistent itching that does not improve with treatment.
• Red, pink, or dark patches of skin.
• Thickened or scaly plaques.
• Raised skin lesions or tumors.
• Swollen lymph nodes.
• Changes in skin color or texture.
• Skin infections caused by damaged skin.
• Unexplained fatigue or weight loss in more advanced cases.

If your eczema symptoms continued to worsen despite treatment with Dupixent, or you were eventually diagnosed with cutaneous T-cell lymphoma after initially being treated for atopic dermatitis, call Hach & Rose, LLP to discuss your situation with our experienced mass tort attorneys.

When Should Persistent Eczema Be Re-Evaluated?

One of the challenges in the emerging Dupixent litigation is that cutaneous T-cell lymphoma can closely resemble eczema, particularly in its early stages. As a result, some patients receive treatment for atopic dermatitis long before physicians recognize that a more serious condition may be present.

The following progression illustrates why additional evaluation may become necessary when symptoms fail to improve.

Not every patient who experiences persistent eczema has lymphoma, and most people who use Dupixent will never develop CTCL. However, plaintiffs in these lawsuits allege that stronger warnings could have prompted earlier evaluation in some patients whose symptoms were not responding as expected.

What Evidence Can Strengthen a Dupixent Lawsuit?

Every case is different, and no single piece of evidence determines whether someone has a viable legal claim. Instead, attorneys evaluate all relevant evidence to understand whether Dupixent may have contributed to a patient’s injuries.

Our attorneys will typically review prescription records, pathology reports, biopsy results, oncology records, treatment plans, and other medical documentation to evaluate whether a patient may have a viable claim.

Many people worry they no longer have their prescription records or cannot remember exactly when they began taking Dupixent. Fortunately, these records can often be obtained from healthcare providers, pharmacies, or insurance companies.

During your consultation, the Dupixent injury lawyers at Hach & Rose, LLP can help determine what information may be available and whether additional records exist to support your claim.

What Compensation May Be Available in a Dupixent Lawsuit?

A lymphoma diagnosis often affects far more than a person’s physical health. Many patients face months of treatment, time away from work, mounting medical bills, and uncertainty about the future.

A successful Dupixent lawsuit may recover compensation for damages and losses such as:

• Past and future medical expenses.
• Chemotherapy, radiation therapy, immunotherapy, or surgery.
• Lost wages and diminished earning capacity.
• Pain and suffering.
• Emotional distress.
• Future medical monitoring.
• Other financial losses related to cancer treatment and recovery.

The value of your claim depends on your diagnosis, treatment, prognosis, and the overall impact the illness has had on your daily life. We work to understand the full impact of this situation so we can include every possible loss in your claim demand.

Frequently Asked Questions About Dupixent Lawsuit Claims

Speak With the Dangerous Drug Lawyers at Hach & Rose, LLP to Learn More About a Potential Dupixent Lawsuit

Being diagnosed with lymphoma after taking a medication you trusted can be devastating. You may be facing ongoing treatment, uncertainty about your future, and questions about whether your illness could have been prevented. We can help you search for those answers.

The attorneys at Hach & Rose, LLP are committed to helping patients and families pursue accountability when dangerous pharmaceutical products allegedly cause serious harm. We understand the challenges that accompany a cancer diagnosis, and we are prepared to explain your legal rights with honesty, compassion, and respect.

If you or a loved one developed cutaneous T-cell lymphoma or another T-cell lymphoma after using Dupixent, call us today at (212) 779-0057 for a free, confidential consultation. We will review your situation, answer your questions, and explain whether you may qualify to participate in the ongoing Dupixent litigation.

You pay no attorney’s fees unless we recover compensation for you.

Get a free consultation